Skip to main content

Table 1 Estimated prices of agents approved to treat prostate cancer

From: The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma

Treatment Cost of treatment alonea Median overall survival benefit
sipuleucel-T $93,000 (median 3 cycles) 25.8 months vs. 21.7 months [9]
enzalutamide $89,952 (median of 8 cycles) 18.4 months vs. 13.6 months [4]
abiraterone $144,950 (median of 14 cycles) 34.7 vs. 30.3 months [6, 59]
docetaxel $25,000 (median of 10 cycles) 18.9 months vs. 16.5 months [60]
cabazitaxel $68,751 (median of 6 cycles) 15.1 months vs. 12.7 months [7]
radium-223 $155,048 (median of 6 injections) 14.9 months vs. 11.3 months [8]
  1. aAs determined by using estimates of average wholesale drug prices retrieved from UptoDate accessed 11/17/2016